01 Jul 2025
// PRESS RELEASE
30 Jun 2025
// FIERCE BIOTECH
30 Jun 2025
// PR NEWSWIRE
About
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Industry Trade Show
Attending
14-18 July, 2025
ChemOutsourcingChemOutsourcing
Industry Trade Show
Attending
08-10 September, 2025
CONTACT DETAILS
Events
Webinars & Exhibitions
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Industry Trade Show
Attending
14-18 July, 2025
ChemOutsourcingChemOutsourcing
Industry Trade Show
Attending
08-10 September, 2025
CORPORATE CONTENT #SupplierSpotlight
https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
https://www.pharmacompass.com/radio-compass-blog/top-first-in-class-drug-candidates-of-2025-ionis-donidalorsen-sanofi-s-fitusiran-cytokinetics-aficamten-await-fda-approval
https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies
https://www.pharmacompass.com/radio-compass-blog/fda-s-landmark-approvals-of-bms-schizo-med-madrigal-s-mash-drug-us-16-5-bn-catalent-buyout-make-it-to-top-10-news-of-2024
https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
https://www.pharmacompass.com/radio-compass-blog/novartis-gsk-sanofi-bms-shell-out-over-us-10-bn-in-dealmaking-as-mid-size-deals-take-centerstage-in-2024
https://www.pharmacompass.com/radio-compass-blog/fda-s-june-2024-list-of-off-patent-off-exclusivity-drugs-sees-rise-in-cancer-hiv-treatments
https://www.pharmacompass.com/radio-compass-blog/fda-approves-record-eight-biosimilars-in-h1-2024-okays-first-interchangeable-biosimilars-for-eylea
https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2023-merck-s-keytruda-emerges-as-top-selling-drug-novo-lilly-sales-skyrocket-due-to-glp-1-drugs
https://www.pharmacompass.com/radio-compass-blog/fda-approvals-rise-49-in-2023-crispr-s-gene-editing-therapy-sees-light-of-day
01 Jul 2025
// PRESS RELEASE
https://news.abbvie.com/2025-06-30-AbbVie-to-Acquire-Capstan-Therapeutics,-Further-Strengthening-Commitment-to-Transforming-Patient-Care-in-Immunology
30 Jun 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/turnstone-once-allied-abbvie-and-takeda-accepts-8m-xoma-buyout
30 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/abbvie-to-host-second-quarter-2025-earnings-conference-call-302493406.html
23 Jun 2025
// PHARMABIZ
20 Jun 2025
// PRESS RELEASE
https://news.abbvie.com/2025-06-20-AbbVie-Declares-Quarterly-Dividend#:~:text=(NYSE%3A%20ABBV)%20today%20declared,its%20dividend%20by%20310%20percent.
19 Jun 2025
// PRESS RELEASE
https://news.abbvie.com/2025-06-18-AbbVie-Announces-New-Data-Demonstrating-Atogepant-QULIPTA-R-AQUIPTA-R-Achieves-Superiority-Across-All-Endpoints-in-Phase-3-Head-to-Head-Study-Compared-to-Topiramate-for-Migraine-Prevention?utm_campaign=generic&utm_medium=social&utm_source=LI&utm_content=other&sf277580172=1
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13800
Submission : 1998-09-01
Status : Active
Type : II
Certificate Number : R1-CEP 1998-093 - Rev 07
Issue Date : 2020-10-09
Type : Chemical and TSE
Substance Number : 994
Status : Valid
NDC Package Code : 0074-5503
Start Marketing Date : 2010-05-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : AbbVie Korea Co., Ltd.
Registration Date : 2005-08-31
Registration Number : 20050831-18-C-100-05
Manufacturer Name : AbbVie Inc.
Manufacturer Address : 1401 Sheridan Road, North Chicago, IL, 60064-4000, USA
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13197
Submission : 1998-04-30
Status : Active
Type : II
Certificate Number : R1-CEP 2016-267 - Rev 00
Issue Date : 2022-03-14
Type : Chemical
Substance Number : 179
Status : Valid
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-05-09
Pay. Date : 2013-09-25
DMF Number : 27155
Submission : 2015-11-10
Status : Active
Type : II
Certificate Number : R1-CEP 1997-001 - Rev 08
Issue Date : 2023-05-23
Type : Chemical
Substance Number : 179
Status : Valid
Certificate Number : R2-CEP 1995-038 - Rev 05
Issue Date : 2019-01-24
Type : Chemical
Substance Number : 1074
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8904
Submission : 1990-12-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13443
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13372
Submission : 1998-09-01
Status : Active
Type : II
Certificate Number : R1-CEP 2006-292 - Rev 00
Issue Date : 2012-09-24
Type : Chemical
Substance Number : 1673
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24315
Submission : 2010-11-30
Status : Active
Type : II
NDC Package Code : 68513-1054
Start Marketing Date : 2011-09-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Certificate Number : R1-CEP 2012-397 - Rev 00
Issue Date : 2019-09-19
Type : Chemical
Substance Number : 2136
Status : Valid
NDC Package Code : 0074-5503
Start Marketing Date : 2010-05-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 0051-0040
Start Marketing Date : 2020-11-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62526-1737
Start Marketing Date : 2023-02-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62526-1912
Start Marketing Date : 2023-02-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 68513-7155
Start Marketing Date : 2023-06-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 68513-1054
Start Marketing Date : 2011-09-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 68513-2320
Start Marketing Date : 2024-06-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Details:
Through the acqusition, Abbvie will leverage Capstan pipeline, including CPTX2309, anti-CD19 CAR-T therapy candidate, currently in Phase 1, in development for the treatment of autoimmune diseases.
Lead Product(s): CPTX2309
Therapeutic Area: Immunology Brand Name: CPTX2309
Study Phase: Phase IProduct Type: Cell and Gene therapy
Recipient: Capstan Therapeutics
Deal Size: $2,100.0 million Upfront Cash: $2,100.0 million
Deal Type: Acquisition June 30, 2025
Lead Product(s) : CPTX2309
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : Capstan Therapeutics
Deal Size : $2,100.0 million
Deal Type : Acquisition
AbbVie to Acquire Capstan, Further Strengthening in Immunology
Details : Through the acqusition, Abbvie will leverage Capstan pipeline, including CPTX2309, anti-CD19 CAR-T therapy candidate, currently in Phase 1, in development for the treatment of autoimmune diseases.
Product Name : CPTX2309
Product Type : Cell and Gene therapy
Upfront Cash : $2,100.0 million
June 30, 2025
Details:
Mavyret (glecaprevir, pibrentasvir) inhibits P-glycoprotein, approved as the only eight-week treatment for three years and older with HCV infection without cirrhosis or with compensated cirrhosis.
Lead Product(s): Glecaprevir,Pibrentasvir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Mavyret
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Enanta Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 11, 2025
Lead Product(s) : Glecaprevir,Pibrentasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Enanta Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Expands MAVYRET® Use for Hepatitis C for Enanta and AbbVie
Details : Mavyret (glecaprevir, pibrentasvir) inhibits P-glycoprotein, approved as the only eight-week treatment for three years and older with HCV infection without cirrhosis or with compensated cirrhosis.
Product Name : Mavyret
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 11, 2025
Details:
The collaboration will leverage ADARx's RNA discovery expertise and proprietary siRNA technology to develop siRNA therapeutics across multiple disease areas, including immunology and oncology.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Oligonucleotide
Recipient: ADARx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $335.0 million
Deal Type: Collaboration May 14, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Recipient : ADARx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
AbbVie Dives Further Into siRNA With $335M Upfront in ADARx Deal
Details : The collaboration will leverage ADARx's RNA discovery expertise and proprietary siRNA technology to develop siRNA therapeutics across multiple disease areas, including immunology and oncology.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : $335.0 million
May 14, 2025
Details:
Emrelis (telisotuzumab vedotin) is a first-in-class c-Met-directed ADC comprising of a c-Met-binding antibody, cleavable linker and the MMAE payload designed to target c-Met expressing cells.
Lead Product(s): Telisotuzumab Vedotin
Therapeutic Area: Oncology Brand Name: Emrelis
Study Phase: Approved FDFProduct Type: Antibody-drug Conjugate
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2025
Lead Product(s) : Telisotuzumab Vedotin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Approves AbbVie's Drug for a Type of Lung Cancer
Details : Emrelis (telisotuzumab vedotin) is a first-in-class c-Met-directed ADC comprising of a c-Met-binding antibody, cleavable linker and the MMAE payload designed to target c-Met expressing cells.
Product Name : Emrelis
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 14, 2025
Details:
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor, small molecule drug candidate, which is indicated for the treatment of giant cell arteritis.
Lead Product(s): Upadacitinib,Undisclosed
Therapeutic Area: Immunology Brand Name: Rinvoq
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2025
Lead Product(s) : Upadacitinib,Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
Details : Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor, small molecule drug candidate, which is indicated for the treatment of giant cell arteritis.
Product Name : Rinvoq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2025
Details:
Venetoclax, a first-in-class BCL-2 inhibitor, functions by selectively targeting cancer cells in the blood and bone marrow. It is indicated for AML & CLL.
Lead Product(s): Venetoclax
Therapeutic Area: Oncology Brand Name: Venclexta
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 21, 2025
Lead Product(s) : Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AbbVie Introduces Venetoclax in India for Treatment of AML and CLL
Details : Venetoclax, a first-in-class BCL-2 inhibitor, functions by selectively targeting cancer cells in the blood and bone marrow. It is indicated for AML & CLL.
Product Name : Venclexta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2025
Details:
Rinvoq (upadacitinib) is a FDA approved selective JAK inhibitor that is being investigated in adult patients with giant cell arteritis in a Phase 3 clinical trial.
Lead Product(s): Upadacitinib,Corticosteroid
Therapeutic Area: Immunology Brand Name: Rinvoq
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2025
Lead Product(s) : Upadacitinib,Corticosteroid
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AbbVie Wins EU Nod for RINVOQ in Adults with Giant Cell Arteritis
Details : Rinvoq (upadacitinib) is a FDA approved selective JAK inhibitor that is being investigated in adult patients with giant cell arteritis in a Phase 3 clinical trial.
Product Name : Rinvoq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2025
Details:
Rinvoq (upadacitinib) is a FDA approved selective JAK inhibitor that is being investigated in adult patients with giant cell arteritis in a Phase 3 clinical trial.
Lead Product(s): Upadacitinib,Corticosteroid
Therapeutic Area: Immunology Brand Name: Rinvoq
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 28, 2025
Lead Product(s) : Upadacitinib,Corticosteroid
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AbbVie gets Positive CHMP Opinion for RINVOQ® in Giant Cell Arteritis Treatment
Details : Rinvoq (upadacitinib) is a FDA approved selective JAK inhibitor that is being investigated in adult patients with giant cell arteritis in a Phase 3 clinical trial.
Product Name : Rinvoq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2025
Details:
Emblaveo (aztreonam-avibactam), a beta-lactamase inhibitor, has been FDA approved for the treatment of adult patients with complicated intra-abdominal infections in patients 18 years and older.
Lead Product(s): Aztreonam,Avibactam,Metronidazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Emblaveo
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 07, 2025
Lead Product(s) : Aztreonam,Avibactam,Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Approves EMBLAVEO™ for Complicated Intra-Abdominal Infections
Details : Emblaveo (aztreonam-avibactam), a beta-lactamase inhibitor, has been FDA approved for the treatment of adult patients with complicated intra-abdominal infections in patients 18 years and older.
Product Name : Emblaveo
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 07, 2025
Details:
Tepkinly (epcoritamab) is an IgG1-bispecific antibody, which is evaluated for the treatment of diffuse large B-cell lymphoma. It is designed to direct cytotoxic T cells selectively.
Lead Product(s): Epcoritamab,Cyclophosphamide,Rituximab
Therapeutic Area: Oncology Brand Name: Tepkinly
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2024
Lead Product(s) : Epcoritamab,Cyclophosphamide,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Two Data Analyses Show Epcoritamab Induces Durable Complete Responses
Details : Tepkinly (epcoritamab) is an IgG1-bispecific antibody, which is evaluated for the treatment of diffuse large B-cell lymphoma. It is designed to direct cytotoxic T cells selectively.
Product Name : Tepkinly
Product Type : Antibody
Upfront Cash : Inapplicable
December 09, 2024
Regulatory Info : DISCN
Registration Country : USA
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Dosage Form : TABLET;ORAL
Brand Name : VICODIN
Dosage Strength : 500MG;5MG
Packaging :
Approval Date : 1983-01-07
Application Number : 88058
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Dosage Form : TABLET;ORAL
Brand Name : VICODIN ES
Dosage Strength : 750MG;7.5MG
Packaging :
Approval Date : 1988-12-09
Application Number : 89736
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Dosage Form : TABLET;ORAL
Brand Name : VICODIN HP
Dosage Strength : 660MG;10MG
Packaging :
Approval Date : 1996-09-23
Application Number : 40117
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Dosage Form : INJECTABLE;INJECTION
Brand Name : ACYCLOVIR
Dosage Strength : EQ 50MG BASE/ML
Packaging :
Approval Date : 1999-07-26
Application Number : 75114
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : Australia
Dosage Form :
Brand Name : Humira
Dosage Strength :
Packaging : 2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Brand Name : Humira
Dosage Strength :
Packaging : 2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Brand Name : Humira
Dosage Strength :
Packaging : 2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Brand Name : Humira
Dosage Strength :
Packaging : 2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Brand Name : Humira
Dosage Strength :
Packaging : 2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Brand Name : Humira
Dosage Strength :
Packaging : 2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Dosage Form : TABLET; ORAL
Proprietary Name : VICODIN HP
Dosage Strength : 660MG;10MG
Approval Date : 1996-09-23
Application Number : 40117
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Dosage Form : TABLET; ORAL
Proprietary Name : VICODIN
Dosage Strength : 500MG;5MG
Approval Date : 1983-01-07
Application Number : 88058
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Dosage Form : TABLET; ORAL
Proprietary Name : VICODIN ES
Dosage Strength : 750MG;7.5MG
Approval Date : 1988-12-09
Application Number : 89736
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Dosage Form : INJECTABLE; INJECTION
Proprietary Name : ACYCLOVIR
Dosage Strength : EQ 50MG BASE/ML
Approval Date : 1999-07-26
Application Number : 75114
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD :
TE Code :
Dosage Form : SYRINGE
Proprietary Name : HUMIRA
Dosage Strength : 40MG/0.8ML
Approval Date :
Application Number : 125057
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Dosage Form : VIAL
Proprietary Name : HUMIRA
Dosage Strength : 40MG/0.8ML
Approval Date :
Application Number : 125057
RX/OTC/DISCN :
RLD :
TE Code :
RLD : Yes
TE Code :
Dosage Form : SOLUTION/DROPS; OPHTHALMIC
Proprietary Name : LASTACAFT
Dosage Strength : 0.25%
Approval Date : 2010-07-28
Application Number : 22134
RX/OTC/DISCN : OTC
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : QULIPTA
Dosage Strength : 10MG
Approval Date : 2021-09-28
Application Number : 215206
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : QULIPTA
Dosage Strength : 30MG
Approval Date : 2021-09-28
Application Number : 215206
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : QULIPTA
Dosage Strength : 60MG
Approval Date : 2021-09-28
Application Number : 215206
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Inspections and registrations
ABOUT THIS PAGE
AbbVie Inc is a supplier offers 23 products (APIs, Excipients or Intermediates).
Find a price of Cyclosporine bulk with DMF, CEP offered by AbbVie Inc
Find a price of Erythromycin bulk with DMF, CEP offered by AbbVie Inc
Find a price of Biperiden Hydrochloride bulk with CEP offered by AbbVie Inc
Find a price of Butorphanol Tartrate bulk with DMF offered by AbbVie Inc
Find a price of Erythromycin Ethyl Succinate bulk with DMF offered by AbbVie Inc
Find a price of Erythromycin Stearate bulk with DMF offered by AbbVie Inc
Find a price of Isoflurane bulk with CEP offered by AbbVie Inc
Find a price of Paricalcitol bulk with DMF offered by AbbVie Inc
Find a price of Ritonavir bulk with CEP offered by AbbVie Inc
Find a price of Atogepant bulk offered by AbbVie Inc
Find a price of Divalproex Sodium bulk offered by AbbVie Inc
Find a price of Elagolix Sodium bulk offered by AbbVie Inc
Find a price of Enflurane bulk offered by AbbVie Inc
Find a price of Erythromycin Thiocyanate bulk offered by AbbVie Inc
Find a price of Foscarbidopa bulk offered by AbbVie Inc
Find a price of Foslevodopa bulk offered by AbbVie Inc
Find a price of Glecaprevir bulk offered by AbbVie Inc
Find a price of Levothyroxine Sodium bulk offered by AbbVie Inc
Find a price of Pibrentasvir bulk offered by AbbVie Inc
Find a price of Terazosin HCl bulk offered by AbbVie Inc
Find a price of Upadacitinib bulk offered by AbbVie Inc
Find a price of Venetoclax bulk offered by AbbVie Inc
Find a price of Eupadaciti Nip Semihydrate bulk offered by AbbVie Inc